trastuzumab-dttb

trastuzumab-dttb (ONTRUZANT) is an FDA-listed pharmaceutical active ingredient. Route of administration: iv (infusion). Current US regulatory status: approved.

ONTRUZANT is a marketed brand name for trastuzumab-dttb. Check FDA Drugs@FDA for the current US label holder and prescribing information.

trastuzumab-dttb has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.